FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE
The FDA has accepted a supplemental application for FILSPARI (SPARSENTAN) from TRAVERE.
Asset / Drug
Drug and asset intelligence for TRAVERE with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.